# TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors

> **NCT04976660** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Tarus Therapeutics, Inc.**

## Conditions studied

- Colorectal Cancer
- Gastric Cancer
- Hepatocellular Carcinoma
- Pancreatic Cancer

## Interventions

- **DRUG:** TT-4

## Key facts

- **NCT ID:** NCT04976660
- **Lead sponsor:** Tarus Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-12-15
- **Primary completion:** 2023-06-01
- **Final completion:** 2023-09-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Tarus is conducting clinical development under a single IND, specifically IND for TT-10 (PORT-6). Tarus has withdrawn Study TT-4-101 under the TT-4 IND; however the TT-4 IND will remain active.
- **Last updated:** 2025-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04976660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04976660, "TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04976660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*